Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

TQH3906 capsules

TQH3906 is an allosteric inhibitor targeting kinase.

Trial Locations (16)

130031

The first hospital of Jilin University, Changchun

135022

Meihekou Central Hospital, Meihekou

200025

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

233000

The First Affilliated Hospital of Bengbu Medical University, Bengbu

300121

Tianjin People's Hospital, Tianjin

410000

Xiangya Hospital of Central South University, Changsha

421000

The First Affiliated Hospital Of University Of South China, Hengyang

430022

Union Hosiptal, Tongji Medical College, Huazhong University of Science And Technolocy, Wuhan

430060

Renmin Hospital of Wuhan University, Wuhan

450000

Henan Provincial People's Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

471002

Luoyang First People's Hospital, Luoyang

510163

First affiliated hospital of guangzhou medical university, Guangzhou

650032

The First Affiliated Hospital of Kunming Medical University, Kunming

733099

Gansu Wuwei Tumour Hospital, Wuwei

030012

Shanxi Provincial People's Hospital, Taiyuan

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY

NCT06754891 - Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease | Biotech Hunter | Biotech Hunter